Market Overview

Janney, Morgan Stanley Say Sarepta's Gene Therapy Remains On Track

Share:
Janney, Morgan Stanley Say Sarepta's Gene Therapy Remains On Track

Sarepta Therapeutics Inc (NASDAQ: SRPT) shares were under pressure this week following a regulatory update that analysts say may have been misunderstood by the market. 

Sarepta shares were down 5 percent at the start of the week against a biotech index that was up 3 percent after the company provided an update on its microdystrophin gene therapy program that investors perceived as being different from what had previously been expected.

The Analysts

Janney analyst Yun Zhong reiterated a Buy rating on Sarepta with a $200 fair value estimate. 

Morgan Stanley analyst Matthew Harrison reiterated an Overweight rating with a $161 price target. 

The Thesis 

In a follow-up discussion with Janney, Sarepta clarified that the pathway for regulatory approval of the new therapy remains the same as what the company had previously indicated and reiterated that a U.S. launch by the end of 2020 remains possible based on positive data from clinical studies, Zhong said in a Tuesday note. 

“Sarepta's active and ambitious pipeline building is on track,” the analyst said. “We continue to see significant upside potential in Sarepta's gene therapy pipeline.”

Janney also pointed out other positives for Sarepta, including that it continues to build manufacturing capacity.

Harrison said Morgan Stanley also didn’t see the announcement that the therapy would require an additional registration study as a significant d from previously announced timelines.

Price Action

Sarepta shares were up 0.22 percent at $110.26 at the time of publication. 

Related Links

Credit Suisse Joins Consensus To Prescribe Sarepta

Morgan Stanley Buys Into Sarepta Amid Sell-Off, Sees $600M Recurring Opportunity In DMD Candidate

Latest Ratings for SRPT

DateFirmActionFromTo
Oct 2019MaintainsOverweight
Sep 2019MaintainsBuy
Aug 2019MaintainsOutperform

View More Analyst Ratings for SRPT
View the Latest Analyst Ratings

Posted-In: Janney Matthew HarrisonAnalyst Color Biotech Price Target Reiteration Analyst Ratings General Best of Benzinga

 

Related Articles (SRPT)

View Comments and Join the Discussion!

Latest Ratings

StockFirmActionPT
SWKSCascendReiterates100.0
IBMWells FargoMaintains140.0
PNCWells FargoMaintains147.0
TWOUDA DavidsonMaintains17.0
IDYAOppenheimerInitiates Coverage On17.0
View the Latest Analytics Ratings
Don't Miss Any Updates!
News Directly in Your Inbox
Subscribe to:
Benzinga Trading Daily
Get pre-market outlook, mid-day update and after-market roundup emails in your inbox.
Market in 5 Minutes
Everything you need to know about the market - quick & easy.
Daily Analyst Rating
A summary of each day’s top rating changes from sell-side analysts on the street.
Thank You

Thank you for subscribing! If you have any questions feel free to call us at 1-877-440-ZING or email us at vipaccounts@benzinga.com

S&P 500 Companies On Track For Double-Digit Earnings Growth, Despite Apple Disappointment

'Halftime Report' Picks For January 8: Amarin, Apple And More